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The typically recommended chemotherapy options in metastatic anal cancer generally yield partial remissions with limited beneﬁt
for the majority of patients. TIP is a regimen containing paclitaxel (Taxol), ifosfamide, and cisplatin that is known to have
signiﬁcant activity in patients with squamous cell cancers of the head and neck as well as in cervical cancer, both of which are
malignancies strongly associated with oncogenic strains of human papilloma virus (HPV). Interestingly, squamous cell cancer of
the anal canal shares an almost identical pathophysiology including causal association with HPV. Due to this, we chose to use the
TIP regimen to treat patients with advanced anal cancer at our institution and report our ﬁndings on three such consecutive
patients. All the patients tolerated the regimen well with manageable side eﬀects and had excellent responses with complete
resolution of PET activity after treatment. Our observations suggest that TIP is highly active for squamous cell cancer of the
anal canal and warrants further study in the treatment of this disease.
1.Introduction
While representing only two percent of digestive tract cancer
[1], the number of anal squamous cell cancer cases has
continued to increase over the last few decades [2]. This
phenomenon has been linked to numerous factors, the most
signiﬁcant of which is infection with human papilloma virus
(HPV)[3].Inthepast,thismalignancywastreatedprimarily
by inguinal node dissection and abdominoperineal resection
(APR), resulting in the need for a colostomy. Five-year sur-
vival rates ranged from forty to seventy percent [4, 5]. Today,
aregimeninvolvingconcurrentradiationandchemotherapy,
the latter utilizing 5-ﬂuorouracil and mitomycin-C, is the
standard of care with surgery being reserved for salvage in
case of residual disease or local recurrence after chemoradia-
tion (CRT). This sphincter-preserving approach has resulted
in the majority of patients being cured with CRT alone
thereby avoiding a permanent colostomy [6, 7].
While this organ-preserving strategy has improved the
overall quality of care and long-term outcomes of patients
with localized disease, options for patients with more
advanced or metastatic anal cancer remain relatively limited
and primarily involve combination chemotherapy. A regi-
men consisting of 5-ﬂuorouracil, and cisplatin has been the
most frequently studied and results in overall response rates
of around sixty percent, most of which are partial responses
[8]. The median survival is approximately twelve months. A
more aggressive combination of mitomycin-C, doxorubicin
and cisplatin followed by bleomycin and CCNU yielded
relativelysimilaroutcomes[9].Smallerreportshaveincluded
carboplatin, doxorubicin, and irinotecan with or without
cetuximab. Again, partial remissions are the norm [10–14].
We present our experience treating patients with recur-
rent, metastatic anal cancer using a regimen consisting of a
combination of paclitaxel, ifosfamide, and cisplatin (TIP).
We chose to use this regimen due to the impressive activity
it has shown in squamous cell cancers of the head and neck
[15] and the uterine cervix [16], both of which share a
striking resemblance to anal cancer. Like anal cancer, they
are both squamouscell malignancies whose pathogenesis has2 Chemotherapy Research and Practice
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Figure 1: (a) The pretherapy anterior (0◦ degree) maximum intensity projection image of the PET/CT study of patient 1 showing multiple
metastatic lesions in bilateral supraclavicular fossa, throughout the mediastinum, hila and in abdominal nodal basins. (b) The six-months
posttherapy anterior (0◦ degree) maximum intensity projection image of the PET/CT study of the patient showing complete resolution of
the previously seen FDG avid lesions.
been strongly associated with oncogenic strains of HPV [17,
18]. Due to this etiopathologic homology, it was conceivable
that anal cancer may respond just as well to this treatment,
and we report the results of our observations here.
2. Methods and Results
The treatment protocol and subsequent response and sur-
vival of three consecutive patients at our institution with
recurrent, advanced squamous cell cancer of the anal canal
are the focus of this paper. All three patients were African
American females in the forty-to ﬁfty-year age range,
with minimal comorbidities, initially treated with 5- ﬂuo-
rouracil and cisplatin concurrently with radiation therapy.
Subsequently, following development of recurrent disease
all patients got the same regimen consisting of paclitaxel
175mg/m2 g i v e no nd a y1 ,i f o s f a m i d e1g / m 2 daily on days 1
to 4 and cisplatin 75mg/m2 o nd a y1 .C y c l e sw e r er e p e a t e d
at 3 week intervals and appropriate supportive measures
including dose adjustments or delays were instituted based
on previously reported experience with the regimen in other
malignancies [15, 16]. All patients received growth factor
prophylaxis to prevent febrile neutropenia.
Case 1. A 46-year-old female presented with complaints
of diﬃculty with bowel movements and anal discomfort
and was found to have an inﬁltrating poorly diﬀerentiated
squamous cell carcinoma on anal mass tissue biopsy. Fine
needle aspiration (FNA) of her bilateral inguinal lymph
nodes was positive for metastatic squamous cell carcinoma
and she was staged as T3N3M0 based on PET/CT imaging.
Treatment with 5FU and cisplatin along with RT resulted in
complete remission which was conﬁrmed by tissue biopsy.
Approximately nine months after completion of her treat-
ment the patient presented with complaints of night sweats,
back pain and had an enlarged supraclavicular lymph node
on the right side of her neck. Imaging with PET/CT showed
very extensive disease that appeared to primarily involve
nodal areas (Figure 1(a)). Of note, there were no lesions
seen in the inguinal lymph nodes or the anal region. Also,
there was no evidence of a head and neck or lung primary
by clinical examination or imaging. The patient underwent
an FNA of the enlarged cervical lymph node which showed
keratinizing squamous cell carcinoma consistent with anal
primary. She was started on TIP chemotherapy every twenty
o n ed a y sw i t hg r o w t hf a c t o rs u p p o r t .C T( w i t h o u tP E T )
done after three cycles showed complete resolution of all
radiographic lesions and a subsequent PET/CT after three
more cycles also showed complete resolution of FDG uptake
(Figure 1(b)). The patient became asymptomatic and was
able to discontinue all analgesics. She completed a total of
six cycles of TIP chemotherapy and remained disease-free on
serial imaging for six months after the ﬁrst documentation
of complete remission (CR). She subsequently recurred
with widespread involvement of lymph nodes in the neck,
mediastinum, right hilum, retroperitoneum, and pelvis and
succumbed to the disease six months later.
Case 2. A 42-year-old female with four months of perirectal
pain and intermittent rectal bleeding was found on examina-
tiontohaveananalmassalongwithpalpableinguinallymph
nodes bilaterally. Biopsies of the primary lesion as well as
the inguinal lymph nodes revealed moderately diﬀerentiated
keratinizing squamous cell carcinoma. A subsequent wholeChemotherapy Research and Practice 3
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Figure 2: (a) The pretherapy anterior (0◦ degree) maximum intensity projection image of the PET/CT study of the patient demonstrating
multiple pleural-based nodular metastatic lesions in the left chest along with prominent FDG uptake also seen in the activated brown fat
tissue in multiple locations. (b) The six-months posttherapy anterior (0◦ degree) maximum intensity projection image of the PET/CT study
of the patient showing complete resolution of the previously seen FDG avid lesions associated with intense bone marrow FDG activity and
increased splenic activity seen due to therapy-induced bone marrow stimulation.
body PET/CT indicated a 5cm anal mass, a 2.3cm enlarged
left iliac chain lymph nodes, enlarged left inguinal lymph
nodes,andslightlyprominentrightinguinalnodes.Basedon
the above information, the patient was staged as T3N3M0
(IIIB) and treated with a 5FU/cisplatin regimen with con-
current radiation. She tolerated this well and remained
disease-free for over a year at which time she developed
persistent left thoracic and back pain. A chest CT indicated
prominent pleural-based densities and pleural thickening in
the left hemithorax with a PET/CT scan showing an area
of intense hypermetabolism in the left pleural compartment
(Figure 2(a)). A CT-guided biopsy of the pleural-based
mass was done, which conﬁrmed the diagnosis of recurrent
squamous cell anal carcinoma after careful comparison of
the histology with that of the original primary tumor. At
this point, the TIP regimen was administered every twenty-
one days, along with growth factor support. The patient
tolerated treatment fairly uneventfully and only had mild
(grade 1 or 2) hematologic and GI toxicities (Table 1). After
the ﬁrst three cycles, a follow-up PET/CT scan indicated
signiﬁcant shrinkage of multifocal lobular-nodular based
metastases in the lung with complete resolution of FDG
uptake (Figure 2(b)). She went on to get a total of six cycles
and remained disease-free for two and a half years. At her
most recent appointment, patient had pleuritic chest pain
and was found to have a mass lining the left hemidiaphragm.
A biopsy was attempted but was unsuccessful due to the dif-
ﬁcult location of the tumor and patient has begun treatment
with TIP with the presumptive diagnosis of recurrent anal
cancer.
Case 3. A 54-year-old female with rectal bleeding and
weight loss was found to have a large anal mass along with
left inguinal adenopathy. A biopsy of her anal mass and
left groin indicated moderately diﬀerentiated squamous
cell carcinoma and she was staged as T4N2M0. A diverting
colostomy was done and the patient was treated with 5FU
and cisplatin with concurrent radiation. Although she had
complete resolution of her primary and inguinal disease,
follow-up CT imaging showed development of a soft tissue
mass in the pelvis deep to the right psoas muscle, also
involving the iliac arteries, with progression of the disease
indicated on further imaging (Figure 3(a)). At this point she
was referred to our institution for further treatment options.
We started her on the TIP regimen which she tolerated
fairly well with only grade 1 or 2 hematologic toxicity
(Table 1). A follow-up PET/CT scan after the second cycle of
chemotherapy, revealed an interval decrease in the size of the
right retroperitoneal mass and a substantial reduction in the
FDG uptake. After two additional cycles, there was further
reduction in tumor size and complete resolution of FDG
uptake per PET/CT (Figure 3(b)). A PET/CT scan done after
two additional cycles revealed stable ﬁndings of persistent
soft tissue density between the L5 vertebral body and the
right psoas muscle with no FDG uptake. The patient had
completed 6 cycles of TIP but was not felt to be resectable
due to vascular involvement and was therefore followed
oﬀ therapy with another PET/CT in two months. This
unfortunately showed disease progression with an increase
in the size of the mass as well as FDG uptake and she became
symptomatic again with pelvic and hip pain. She was treated4 Chemotherapy Research and Practice
Table 1: Summary of patient characteristics and treatment outcomes with TIP.
Patient
Stage at
original
diagnosis
Treatment at
original
diagnosis
Presentation at
recurrence
Treatment at
recurrence
Toxicity besides
alopecia with TIP:
all were NCI grade 1
or 2 unless
otherwise speciﬁed
Best response
to TIP by
RECIST
criteria
Duration of
response
with TIP
Survival
since
recurrence
Case 1-46-
year-old
female
T3N3M0 CRT with
5FU/cisplatin
Biopsy-proven
metastatic disease
in chest and
abdomen twelve
months after
original diagnosis
TIPx6 cycles
then TIPx2
cycles then
FOLFOX6
modiﬁed x1
cycle
Anemia
Thrombocytopenia
PN (grade 3)
CR per CT
after 3 cycles
conﬁrmed by
PET/CT after 3
more cycles
6 months 14 months
Case 2-42-
year-old
female
T3N3M0 CRT with
5FU/cisplatin
Biopsy-proven
metastatic disease
in chest twenty two
months after
original diagnosis
TIPx6 cycles
Anemia
Thrombocytopenia
Diarrhea
Syncope
PN
CR per
PET/CT after 3
cycles
2 years and
six months
2 years and
six months
thus far
Case 3-54-
year-old
female
T4N2M0 CRT with
5FU/cisplatin
Metastatic disease
in pelvis ﬁve
months after
original diagnosis
TIPx7 cycles
then RT to
right
paraspinal
mass
Anemia
Thrombocytopenia
Nausea
CR per PET
after 4 cycles
(PR per CT)
4m o n t h s
17 months
thus far
(patient
alive with
disease)
CRT: chemo radio therapy
5FU: ﬂuorouracil
CR: complete remission
PR: partial remission
RECIST: response evaluation criteria in solid tumors
FOLFOX: infusional ﬂuorouracil + leucovorin + oxaliplatin.
PN: Peripheral neuropathy.
with another cycle of TIP with symptomatic improvement
but was unable to continue treatment due to socioeconomic
and other personal reasons. She has since received palliative
RT to the psoas mass with symptomatic relief and is alive
with disease at the time of this writing.
3. Discussion
Squamous cell cancer of the anal canal comprises about
two percent of the malignancies of the GI tract [1] and is
now well known to be strongly associated with infection by
oncogenic strains of HPV [3]. Clinically, it is associated with
substantial morbidity and suﬀering including rectal bleeding
and pain which is often severe. In the past, the mainstay
of treatment was an APR which left patients with lifelong
colostomies and all the accompanying quality-of-life issues.
However, with the advent of an organ-sparing approach
consisting of concomitant radiation and chemotherapy, the
latter including mitomycin-C and cisplatin, approximately
eighty percent of patients can be cured without the need for
morbid surgery [19, 20]. The treatment regimen incorpo-
rates the use of 5-FU (1000mg/m2 per day by continuous
infusion days 1 through 4 and 29 through 32), mitomycin
(10 to 15mg/m2 on day 1 only), and an intermediate
dose of radiation therapy (30Gy). Due to the substantially
higher hematologic toxicities associated with mitomycin-
C, its substitution by cisplatin has been investigated in
cm
(a)
cm
(b)
Figure 3: (a) The pretherapy anterior (0◦ degree) maximum
intensity projection image of the PET/CT study of the patient is
shown with the red arrows indicating the right internal iliac and left
commoniliaclesions.(b)Thefour-monthsposttherapyanterior(0◦
degree) maximum intensity projection image of the PET/CT study
shows resolution of previously seen FDG avid bilateral iliac lesions
while the arrow indicates the FDG activity at left antecubital fossa
injection site.Chemotherapy Research and Practice 5
recent studies with conﬂicting results. In the RTOG 98-11
trial, there was no signiﬁcant diﬀerence in ﬁve-year disease-
free survival (54 versus 60 percent for the cisplatin and
mitomycin groups, respectively; P = .17) or overall survival
(70 versus 75 percent; P = .10). However, colostomy rates
(cumulative rate 19 versus 10 percent; P = .02) were
signiﬁcantlyhigherintheinductioncisplatin/5-FUarm[21].
The ACT II study on the other hand showed no diﬀerence
between mitomycin-C or cisplatin containing regimens in
any of the above parameters including colostomy rates [22].
The above issues notwithstanding, the high cure rates
achievedwithCRTalonerepresentasubstantialstepforward
in the quality of care from the days of universal APRs.
The beneﬁt of this advancement however has been limited
to patients with localized disease. Those that have more
advanced disease at diagnosis or that recur with unresectable
disease still have disappointingly few options available to
them. Given that the vast majority of patients with anal
cancer are cured with CRT with or without salvage surgery,
it has been diﬃcult to get enough numbers of patients with
recurrent or metastatic disease to do large clinical trials in
this setting. In terms of systemic therapy, the combination
of 5FU and cisplatin has been the most extensively studied
and reported [8]. Response rates have been between ﬁfty to
sixty percent with, most of which are partial. Similar results
have been noted in other studies using combinations such as
mitomycin,doxorubicinandcisplatinfollowedbybleomycin
and CCNU or single agents like carboplatin, irinotecan with
or without cetuximab [9–14].
All of the above regimens mostly induce a partial
response (PR) which is certainly helpful in controlling the
disease for a period of time. They typically however, do
not appear to induce complete remissions (CR). This also
limits their usefulness in patients with advanced disease
that is potentially amenable to local therapy. In this setting,
therefore, it would be very helpful to have a regimen that
induces a high-rate of response including a high proportion
of CRs so that those who have a chance of getting potentially
curative local therapy may be more likely to do so. Since
the small numbers make it diﬃcult to generate high quality
data deﬁning a standard in this situation, extrapolation
from other diseases with biologic similarities to anal cancer
w o u l db ear e a s o n a b l es t r a t e g yt oﬁ n dm o r ea c t i v et r e a t m e n t
options for this subset of patients. It has been noted that
squamous cell carcinoma of the anal canal is strikingly
similar to squamous cell cervical cancer and squamous cell
carcinoma of the head and neck both in terms of histology
and a strong causative association with HPV infection [3, 17,
18]. Patients with these head and neck and cervical cancers
have been shown to have impressive responses following
the administration of TIP chemotherapy [15, 16]. In the
study with recurrent head and neck cancer by Shin et
al. [15] the overall response rate with TIP was 58% with
17% complete remissions. In the subset of patients with
metastatic disease, the response rate was even higher at
80%. The toxicity was primarily hematologic with a 27%
incidence of febrile neutropenia albeit in the absence of
growth factor prophylaxis. The only other signiﬁcant toxicity
besides alopecia and nausea was peripheral neuropathy
which was grade 3 in 5% of the patients. Similar results
were reported by Zanetta et al. with the use of TIP for
recurrent cervical cancer [16]. Given the pathobiologic
similarity of these malignancies to squamous cell cancer of
the anal canal, it is conceivable that similar high quality
responses may be attainable in this disease as well. Our
experience with the three patients presented here certainly
point to signiﬁcant activity of TIP in anal cancer. All the
patients had a rapid and dramatic response with complete
remission (CR) per PET scanning in all three cases and
a CR by RESIST criteria in two of the three. Especially
interesting is the second patient who remained disease-free
more than two years after completion of TIP chemotherapy
for her biopsy proven metastatic recurrence. It must be
emphasized that the TIP regimen typically requires inpatient
administration and carries signiﬁcant risk of hematologic
toxicity. In the study by Shin et al. [15] even though anemia
and thrombocytopenia were mostly mild or moderate, the
incidence of febrile neutropenia was 27% in the absence
of growth factor prophylaxis. It is therefore imperative that
patients be carefully selected for performance status and
tolerance and closely monitored for supportive care during
treatment as per lessons gleaned from the use of this regimen
in other cancers. We chose to use prophylactic growth factor
support to prevent febrile neutropenia and none of our
patients had this toxicity. As long as these guidelines are
followed, patients appear to tolerate the regimen remarkably
well and only one patient in our series had a grade 3 adverse
event which was peripheral neuropathy (Table 1).
In conclusion, this is the ﬁrst report of the use of TIP
chemotherapy in anal cancer. We believe our observations
suggest that this is a highly active regimen in this setting
and may be a promising avenue of future study not only
for patients with recurrent or metastatic disease but also for
treatment of selected high-risk patients with localized and
potentially curable disease.
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